Accustem Sciences Inc. (ACUT)
Accustem Sciences Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in New York City, NY, US. The stock last traded at $0.12, up 0.00% on the session, giving a market capitalisation of $1.9M. On trailing twelve-month figures it carries a trailing P/E of -1.13, a net margin of -1680.0%. Its beta of 1.87 implies it has historically moved more than the broad market.
AccuStem Sciences, Inc. operates as a life science firm committed to improving the outlook for individuals battling cancer. Its primary innovation is the StemPrintER technology, an advanced multi-gene prognostic assay designed to predict the likelihood of recurrence for patients with Endocrine receptor-positive /HER2- breast cancer. The company also offers Spare, a related diagnostic tool that expands upon StemPrintER by incorporating two additional clinical markers. AccuStem Sciences, Inc. is based in New York, New York.
Accustem Sciences Inc. is most often compared with the following Healthcare names: